STOP-NIDDM

AcronymDefinition
STOP-NIDDMStudy to Prevent Non-Insulin-Dependent Diabetes Mellitus
References in periodicals archive ?
Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M for The STOP-NIDDM Trial Research Group.
The STOP-NIDDM trial was one of several recent studies pointing to the importance of postprandial glucose values.
In a subanalysis of the STOP-NIDDM trial, acarbose slowed the progression of intimal-medial thickness in subjects with IGT, the first placebo-controlled, prospective study to show that counterbalancing of postprandial hyperglycemia may be vasoprotective (Stroke 2004;35:1073-8).
STOP-NIDDM was one of several recent studies pointing to the importance of postprandial glucose values, which have until recently received less attention than fasting glucose.
STOP-NIDDM was an international randomized trial in which 1,368 patients with impaired glucose tolerance were randomized to acarbose--an alpha-glucosidase inhibitor that delays glucose absorption--or placebo.
Zeymer focused on a secondary end point of the STOP-NIDDM (Study to Prevent Non-Insulin-Dependent Diabetes Mellitus) trial.
Markolf Hanefeld of Dresden (Germany) University of Technology, separately presented another STOP-NIDDM secondary analysis; this one aimed at picking out subgroups of patients with IGT in whom acarbose was particularly beneficial.